3 active not recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 3 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Mitomycin C: new trials by email Literature Review of Mitomycin C trials Research Report on Mitomycin C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) TAR-200, Mitomycin C, Gemcitabine - Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 272 | 2024-04-09 | 2026-11-03 |
| REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c - Anal Cancer | Phase 2 / Phase 3 | Active not recruiting | University of Cincinnati | 33 | 2023-08-14 | 2025-12-18 |
| Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Atezolizumab, Biopsy of Bladder, Cisplatin - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 475 | 2019-06-03 | 2026-08-28 |
Anus Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Urinary Bladder Neoplasms (1)
Janssen Research & Development, LLC (1) · National Cancer Institute (NCI) (1) · University of Cincinnati (1)
United States (3) · Argentina (1) · Belgium (1) · Brazil (1) · China (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Poland (1) · Romania (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Parminder Singh (1)
2023 (1), U10CA180888 (1)